Immunotherapeutic uses of CpG oligodeoxynucleotides

By D. Klinman. Nature reviews. Immunology, 2004

1,018 citations recorded by the source corpus.

Subfields: Immunology

View Paper: https://www.semanticscholar.org/paper/12b934af747670989ddf04353fa5d4254cdf0232

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. Shizuo Akira
2. R. Medzhitov
3. A. Krieg
4. Taro Kawai
5. Tadatsugu Taniguchi
6. H. Yanai
7. K. Honda
8. O. Takeuchi

Citations in the corpus

• Toll-like receptor function and signaling. (2006, background): “At least 3 distinct classes of oligonucleotides containing CpG motif have been reported.(35) Conventional CpG DNA, also called K-type CpG DNA or CpG-B, has the potent ability to activate B cells and induce cytokine production from macrophages.”
• IRF-7 is the master regulator of type-I interferon-dependent immune responses (2005, background): “Because TLR9 signalling is the focus of much attention in the context of the regulation of adaptive immune response”
• IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors (2006, background): “Splenic pDCs from Irf7 −/− mice have a marked defect in type I IFN gene induction following infection with viruses (the dsDNA virus HSV or the ssRNA virus VSV) or exposure to synthetic TLR ligands ( CpG-A”
• Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. (2005, background): “mined whether CpG ODNs are efficient adjuvants for vaccineinduced human cytolytic T cell responses (7).”
• Toll-like receptors in antiviral innate immunity (2013, background): “TLR9 can also be stimulated by three different classes of synthetic CpG oligodeoxynucleotides (ODNs)mediating type I IFNproduction andBcell activation [135,136].”
• Immunosuppressive networks in the tumour environment and their therapeutic relevance (2005, background): “Given the potential benefit of activating plasmacytoid DCs, the use of oligonucleotides as an adjuvant to activate plasmacytoid DCs has been suggested to treat various diseases including human tumour”
• Origins, structures, and functions of circulating DNA in oncology (2016, neutral): “ATF1, activating transcription factor 1; IRAK, IL-1 receptoractivated kinase; JNKK1, c-JUN N-terminal kinase (JNK) kinase 1; NIK, NF-kB-inducing kinase; TRAF6, tumor-necrosis factor receptor-associated factor 6 (from Klinman [215]) Cancer Metastasis Rev”
• Self-assembled multivalent DNA nanostructures for noninvasive intracellular delivery of immunostimulatory CpG oligonucleotides. (2011, background): “ODNs have been actively exploited as promising therapeutic agents due to their high solubility, design flexibility, and good safety.(35,45) However, naked ODNs are usually not efficiently cell-permeable in the absence of transfection agents (e.”
• Indoleamine 2,3-dioxygenase and tumor-induced tolerance. (2007, background): “CpG ODN are potent immunologic activators (115) and are currently in phase III clinical trials as an immunostimulatory agent in patients with lung cancer (116, 117).”